Thales Introduces CipherTrust Intelligent Protection to Automate Security for Sensitive Data
Building on the success of the CipherTrust Data Security Platform, Thales has released CipherTrust Intelligent Protection, a new solution that further simplifies operational complexity and strengthens data security efforts with automated processes that discover, protect and control sensitive data anywhere. Faced with overwhelming data growth, organisations can use CipherTrust Intelligent Protection to safeguard all sensitive information without the added cost and complexity of traditional data protection products and services. Once the sensitive data has been discovered and classified based on vulnerability and other risk profiles, the new solution automatically protects at-risk data with encryption and robust access controls.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005012/en/
©Thales
CipherTrust Intelligent Protection is a solution configuration within the Thales CipherTrust Data Security Platform that works together with CipherTrust Manager, CipherTrust Data Discovery and Classification, and CipherTrust Transparent Encryption –an all-in-one solution that delivers a unified approach. CipherTrust Intelligent Protection addresses the evolving challenges of regulatory compliance by facilitating accelerated time to compliance with automatic data protection controls. It also offers easy-to-use, pre-programmed tools to quickly and effectively secure unstructured sensitive data on-premises and in the cloud.
Reducing complexity in data protection with integrated automation
As organisations contend with expanding datasets, permanent work-from-home or hybrid office schemes, and the increased use of multi-cloud services, lack of visibility places their sensitive data at risk. Thales’s 2021 Data Threat Report found that the use of cloud-based infrastructure exposes new risks as an organisation’s data footprint expands and raises concerns about operational complexity. Less than a quarter (24%) of respondents said they have complete knowledge of where their data is stored. Configurable policies with built-in templates to rapidly discover and classify unstructured sensitive data can be used to protect data on-premises and in the cloud.
“Cloud computing services and data security requirements will only grow more complex as organisations work to keep pace with new and evolving work environments,” said Todd Moore, VP Encryption Products at Thales. “Increased operational complexity demands simplified security procedures, and CipherTrust Intelligent Protection makes it significantly easier for companies to safeguard data proactively based on known vulnerabilities and data privacy regulations, which reduces overall business risk. Intelligent Protection provides the automation so customers can confidently take data security measures into their own hands with an all-in-one solution.”
Accelerating time-to-compliance
Today’s businesses and organisations must remain in compliance with a broad range of regulations and mandates, including GDPR, CCPA, HIPAA, and PCI DSS. Data privacy laws and regulations are never static – new ones appear regularly and existing ones often get enhanced, making it difficult for you to keep pace. An integrated and automated solution helps eliminate blind spots and human error, making a considerable difference in complying with various regulations.
"This all-in-one solution combines the best of the Ground Labs' data discovery technology with Thales’ CipherTrust Data Security Platform to give organizations the power to automatically discover, classify and keep sensitive data secure, whether it's on-premises or in the cloud," said Stephen Cavey, co-founder and chief evangelist of Ground Labs. “Our partnership with Thales underscores our common mission to protect our customers, regardless of where they store their data - and through this collaboration, we can better meet the data security needs of customers today and in the future."
“Managing risk is becoming increasingly burdensome for IT leaders not only because of the volume and sophistication of cyber-attacks but also due to the operational complexity of managing disparate security products and services,” said Frank Dickson, Program Vice President, Security & Trust, IDC. “Truly integrated platforms that automate the discovery, classification and protection of sensitive data can help organisations reduce both hard costs and risks associated with stitching together multivendor solutions while addressing and mitigating soft costs by simplifying data security operations and compliance.”
Uncover and Close Security Gaps
Finding a way to rapidly identify data compliance gaps and potential security risks is of paramount importance. Using the high performance and accurate discovery engine is an extremely useful way to find data subject to regulations that organizations may not realize even exists. CipherTrust Data Discovery and Classification provides risk-based guidance on what specific data to encrypt. Linking this discovery process to CipherTrust Transparent Encryption provides organizations with a fast track to automatically uncover and close security gaps.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005012/en/
Contact information
PRESS
Thales, Media Relations
Security
Constance Arnoux
+33 (0)6 44 12 16 35
Constance.arnoux@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
